Skip to main content

Table 1 Demographics, clinical and surgical characteristics of the women versus men in the cohort before propensity score matching

From: Sex differences following percutaneous coronary intervention or coronary artery bypass surgery for acute myocardial infarction

Variable PCI with stent CABG
Women
(n = 13,514)
Men
(n = 46,693)
STD Women
(n = 1762)
Men
(n = 5565)
STD
Age (years) 71.2 ± 11.7 61.8 ± 13.4 0.75 69.3 ± 9.9 65.2 ± 11.7 0.38
Comorbid conditions       
 Diabetes mellitus 7374 (54.6%) 15,866 (34.0%) 0.42 1212 (68.8%) 2644 (47.5%) 0.44
 Hypertension 10,448 (77.3%) 27,716 (59.4%) 0.39 1420 (80.6%) 3734 (67.1%) 0.31
 Dyslipidemia 5901 (43.7%) 21,987 (47.1%) − 0.07 681 (38.6%) 1942 (34.9%) 0.08
 Heart failure hospitalization 1647 (12.2%) 2041 (4.4%) 0.29 265 (15.0%) 435 (7.8%) 0.23
 Peripheral arterial disease 807 (6.0%) 1412 (3.0%) 0.14 137 (7.8%) 339 (6.1%) 0.07
 Prior stroke hospitalization 2550 (18.9%) 4998 (10.7%) 0.23 353 (20.0%) 901 (16.2%) 0.10
 COPD 945 (7.0%) 4203 (9.0%) − 0.07 111 (6.3%) 678 (12.2%) − 0.20
 Liver cirrhosis 245 (1.8%) 905 (1.9%) − 0.01 19 (1.1%) 122 (2.2%) − 0.09
 Malignancy 773 (5.7%) 1860 (4.0%) 0.08 60 (3.4%) 177 (3.2%) 0.01
 Autoimmune disease 434 (3.2%) 552 (1.2%) 0.14 43 (2.4%) 65 (1.2%) 0.10
 Chronic kidney disease 3689 (27.3%) 7024 (15.0%) 0.30 598 (33.9%) 1480 (26.6%) 0.16
 Dialysis 980 (7.3%) 1371 (2.9%) 0.20 115 (6.5%) 240 (4.3%) 0.10
Charlson’s Comorbidity Index score 3.4 ± 2.1 2.5 ± 1.8 0.47 3.8 ± 2.0 3.1 ± 2.0 0.32
Bleeding history       
 Major bleeding 964 (7.1%) 2180 (4.7%) 0.10 94 (5.3%) 247 (4.4%) 0.04
 GI bleeding 2758 (20.4%) 5721 (12.3%) 0.22 305 (17.3%) 734 (13.2%) 0.11
 ICH 200 (1.5%) 548 (1.2%) 0.03 22 (1.2%) 56 (1.0%) 0.02
 Anemia 506 (3.7%) 608 (1.3%) 0.16 49 (2.8%) 73 (1.3%) 0.10
Hospital level       
 Medical center (teaching hospital) 6454 (47.8%) 23,883 (51.1%) − 0.07 1185 (67.3%) 3762 (67.6%) − 0.01
 Regional/district hospital 7060 (52.2%) 22,810 (48.9%) 0.07 577 (32.7%) 1803 (32.4%) 0.01
Type of CABG       
 On pump 1447 (82.1%) 4577 (82.2%)  < 0.01
 Off pump 315 (17.9%) 988 (17.8%)  < 0.01
Endarterectomy     79 (4.5%) 274 (4.9%) − 0.02
Concomitant valve surgery 136 (7.7%) 316 (5.7%) 0.08
Valve location and type       
 Aortic valve replacement 48 (2.7%) 131 (2.4%) 0.02
 Mitral valve repair 30 (1.7%) 80 (1.4%) 0.02
 Mitral valve replacement 60 (3.4%) 123 (2.2%) 0.07
Details of coronary stenting       
 Type of stent       
  BMS 10,076 (74.6%) 34,400 (73.7%) 0.02
  DES 3438 (25.4%) 12,293 (26.3%) − 0.02
 Number of stenting 1.03 ± 0.17 1.03 ± 0.16 0.03
Number of intervened/grafted vessels       
 1 10,118 (74.9%) 37,482 (80.3%) − 0.13 134 (7.6%) 298 (5.4%) 0.09
 2 2984 (22.1%) 8201 (17.6%) 0.11 339 (19.2%) 911 (16.4%) 0.08
 3 412 (3.0%) 1010 (2.2%) 0.06 1289 (73.2%) 4356 (78.3%) − 0.12
Antiplatelet therapy at discharge       
 Aspirin 9675 (71.6%) 38,780 (83.1%) − 0.28 665 (37.7%) 2597 (46.7%) − 0.18
 Clopidogrel/ticlopidine 11,027 (81.6%) 41,574 (89.0%) − 0.21 425 (24.1%) 1496 (26.9%) − 0.06
 Antiplatelet therapy       
  Single 4089 (30.3%) 8675 (18.6%) 0.27 1686 (95.7%) 5204 (93.5%) 0.10
  Dual 9425 (69.7%) 38,018 (81.4%) − 0.27 76 (4.3%) 361 (6.5%) − 0.10
Other medications at discharge       
 Statin 6357 (47.0%) 26,159 (56.0%) − 0.18 431 (24.5%) 1447 (26.0%) − 0.04
 Beta-blocker 6909 (51.1%) 26,955 (57.7%) − 0.13 563 (32.0%) 1934 (34.8%) − 0.06
 ACEI/ARB 7683 (56.9%) 28,702 (61.5%) − 0.09 528 (30.0%) 1492 (26.8%) 0.07
 OAC drugs 203 (1.5%) 792 (1.7%) − 0.02 59 (3.3%) 251 (4.5%) − 0.06
 OHA drugs 4457 (33.0%) 10,819 (23.2%) 0.22 604 (34.3%) 1557 (28.0%) 0.14
 Insulin 1333 (9.9%) 1753 (3.8%) 0.24 283 (16.1%) 437 (7.9%) 0.26
 PPI 901 (6.7%) 2233 (4.8%) 0.08 111 (6.3%) 299 (5.4%) 0.04
 NSAID 2763 (20.4%) 9253 (19.8%) 0.02 284 (16.1%) 1029 (18.5%) − 0.06
Follow-up (years) 2.8 ± 2.7 3.4 ± 2.8 − 0.21 3.2 ± 3.4 3.8 ± 3.6 − 0.16
  1. Data were given as frequency (percentage) or mean ± standard deviation
  2. PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, STD standardized difference, COPD chronic obstructive pulmonary disease, GI gastrointestinal, ICH intracranial haemorrhage, BMS bare metal stent, DES drug-eluting stent, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, OAC oral anticoagulants, OHA oral hypoglycemic agent, PPI proton pump inhibitor